Please use this identifier to cite or link to this item:
Title: Potential Hepatoprotective Role of Galectin-3 during HCV Infection in End-Stage Renal Disease Patients
Authors: Lukic R.
Gajovic N.
Jovanovic I.
Jurisevic M.
Mijailovic Z.
Maric V.
Popovska Jovicic, Biljana
Arsenijevic, Nebojsa
Issue Date: 2017
Abstract: © 2017 Ruzica Lukic et al. Hepatitis C virus infection (HCV), one of the greatest causes of liver disease, is a frequent complication in patients with end-stage renal disease (ESRD) on dialysis. ESRD is defined as decreased glomerular filtration and also accompanied by impaired function of the immune system. Galectin-3 is a β-galactoside-binding lectin, involved in various biological processes including pathogenesis of chronic renal disease. The aim of our study was to estimate disease severity in ESRD HCV+ patients and analyze the serum concentrations of IL-1β, IL-4, IL-23, and IL-6; anti-HCV antibodies; and galectin-3. Also, we attempted to determine potential correlation between galectin-3 level and parameters of disease severity ALT and AST. Our results showed decreased levels of ALT and AST (p=0.00), demonstrating less liver destruction in ESRD HCV+ patients in comparison to HCV+ patients. Increased levels of IL-6 (p=0.03) implicate a hepatoprotective role of IL-6 in these patients. Also, level of galectin-3 (p=0.00) in the serum of ESRD HCV+ patients was higher than that of HCV+ patients. This alteration was accompanied with negative correlation between galectin-3 and AST and ALT, respectively (p=0.029; p=0.033). The presence of increased systemic levels of IL-6 and Gal-3 in ESRD HCV+ patients may be an attempt to counteract or limit ongoing proinflammatory processes and to downregulate chronic inflammation, suggesting the new aspects of HCV infection in ESRD patients.
Type: article
DOI: 10.1155/2017/6275987
ISSN: 0278-0240
SCOPUS: 2-s2.0-85018802318
Appears in Collections:Faculty of Medical Sciences, Kragujevac

Page views(s)




Files in This Item:
File Description SizeFormat 
10.1155-2017-6275987.pdf1.63 MBAdobe PDFThumbnail

This item is licensed under a Creative Commons License Creative Commons